

May 22, 2020

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Sirs,

Sub: Clarification / Confirmation on news item appearing in “Media/Publication”

Please refer to your query seeking clarification on the recent news item which appeared in the website “www.economictimes.com” dated May 21, 2020 captioned “Strides Pharma to conduct trials in India for potential COVID-19 drug”.

In this regard, we wish to submit that:

- Company made a press release on April 29, 2020 titled “Strides develops and commences export of Favipiravir antiviral tablet”, which was also filed with the Stock Exchanges on the same day

The said press release stated: *“the Company to immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available to Indian patients expeditiously”*.

- Further, on May 20, 2020 Company announced financial results for the Quarter and Financial Year ended March 31, 2020 post market hours.
- Company hosted an earnings call at 08.30 hrs IST on May 21, 2020 with the Investors in which the Senior Management interacted with Investors on the earnings. Details of the earnings call with dial-in number for participating in the earnings call was filed with the Stock Exchanges on May 19, 2020.
- During the earnings call on May 21, 2020, as a reply to a query by a participant seeking update on the approval status on Favipiravir from Indian Drug Authorities, we stated that we have approval from the Indian Drug Authorities for conducting the studies and we shall commence the same soon.

However, few media reports reported that the Company has approval for conducting trials in India for potential COVID-19 drugs.

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

- Post the earnings call, on queries from few media houses on May 21, 2020 for further information on Favipiravir, we clarified as under:

“We have approval from the Indian Drug Authorities for conducting human studies.

We would like to clarify that our approval is for carrying out bio-equivalence study to the innovator product (Avigan).

We will keep the stock exchanges and other stakeholders informed on any further developments on this”.

We wish to state that the development mentioned in the news article referred above is not material that would have warranted a disclosure as required under Regulation 30 of the SEBI (LODR) Regulations, 2015.

We request you to take the above on record.

Thanks & Regards
For **Strides Pharma Science Limited**



Manjula Ramamurthy
Company Secretary



Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India

Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India

Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com